

NASDAQ: OTLK
outlooktherapeutics.com



OUTLOOK THERAPEUTICS

*Enhancing the Treatment
of Retinal Disease*

Corporate Presentation
September 2026

Disclaimer

This presentation may contain or contains “forward-looking statements” about Outlook Therapeutics, Inc. (“Outlook Therapeutics” or the “Company”) based on management’s current expectations, which are subject to known and unknown uncertainties and risks. Words such as “can,” “could,” “expect,” “explore,” “initiate,” “intend,” “may,” “plan,” and “potential,” the negatives to any such words, and variations of these words or similar expressions are intended to identify forward-looking statements. These forward-looking statements include, among others, statements about expectations concerning the therapeutic potential of LYTENAVA™ as a treatment of wet AMD; expectations concerning decisions of regulatory bodies, and the timing thereof; the market opportunity for LYTENAVA™; plans for continued engagement with the FDA; actions or advice of regulatory agencies and Outlook Therapeutics’ ability to obtain and maintain regulatory approval for LYTENAVA, as well as favorable pricing and reimbursement; the success of our commercial launch, marketing, and selling of LYTENAVA™ in the US, Germany, Austria, and the UK; our plans for commercial launch of LYTENAVA™ in additional countries in Europe and other locations and timing thereof; our commercialization strategy; Outlook Therapeutics’ ability to obtain and maintain strategic business partnerships and collaborations; and other statements that are not historical fact. Our actual results could differ materially from those discussed due to a number of factors, including, but not limited to, the risks associated with developing and commercializing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, the risk of delays, interruptions, or failures in the manufacturing and supply of Outlook Therapeutics’ products; the risk of potential future litigation, governmental investigations, and other actions; the sufficiency of our resources, unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions (including the long-term impacts of ongoing overseas conflicts, tariffs and trade tensions, fluctuations in inflation and interest rates and other economic uncertainty), as well as those risks detailed in our filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the SEC on December 19, 2025, and other filings with the Securities and Exchange Commission. Moreover, Outlook Therapeutics operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied.

Now FDA Approved!

LYTENAVATM
bevacizumab-vikg injection

Only FDA-Approved Ophthalmic Formulation of
Bevacizumab for the Treatment of Wet AMD

Condensed Important Safety Information

- Consistent safety profile across 5 clinical trials
- CONTRAINDICATIONS:**
 - Ocular or periocular infections,
 - Active intraocular inflammation,
 - Known hypersensitivity to bevacizumab products or any of the ingredients in LYTENAVA
- WARNINGS AND PRECAUTIONS:**
 - Intravitreal injections have been associated with endophthalmitis and retinal detachments.
 - Increases in intraocular pressure have been noted post-injection (up to 60 minutes) while being treated with LYTENAVA.
 - Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LYTENAVA clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors.

1. Please see the full Important Safety Information and Prescribing Information for complete safety details available at lytenava.com/ISI

Table 1. Common Adverse Reactions (≥1%)¹

Adverse Reactions	LYTENAVA (n=601)	Ranibizumab (n=345)
Conjunctival hemorrhage	4%	3%
Eye pain	2%	1%
Vitreous floaters	2%	1%

Less common ocular adverse reactions reported in the study eye <1% of patients treated with LYTENAVA were corneal abrasion, dry eye, eye irritation, and intraocular pressure increased

Corporate Highlights

Commercial biopharmaceutical company dedicated to developing therapies for the preservation of vision

Lead product, LYTENAVA™, is the only FDA and EMA approved ophthalmic formulation of bevacizumab for the treatment of wet AMD

LYTENAVA™

(bevacizumab-vikg; bevacizumab gamma)

United States

Received FDA Approval July 24, 2026

U.S. Commercial Launch planned before calendar year-end 2026

12 years of exclusivity under the Biologics Price Competition and Innovation Act

Europe

Commercial Launch Underway

**Initial Launch Territories
Germany, United Kingdom, and Austria**

Significant United States Market Opportunity

Project >\$500 Million Annual Sales Base Case By 2030

\$8.5 Billion Total U.S. Anti-VEGF Retina Market¹

3.6 Million

Estimated Number of Select Retina Off-Label Repackaged Bevacizumab Injections in 2025²

Off-Label Repackaged Bevacizumab
Predominantly Used in wAMD^{1,2,3}

2.2M

wAMD Injections
in US

1.4M

Injections related to other
indications in US

Advancing Commercial Infrastructure to Support U.S. Launch

- Advancing payer engagement and scaling commercial supply
- Refreshing customer segmentation and targeting to maximize market adoption
- Planning HCPCS code submission in calendar year Q3 to support reimbursement strategy
- Building the commercial team while incorporating feedback from key stakeholders
- Updating commercialization strategy based on new biosimilar market dynamics
- Executing on initiatives designed to support a successful commercial launch

Pricing Strategy Designed to Support Broad Access

A thoughtful pricing philosophy informed by the needs of patients, providers and payers



Patient Affordability

- Patient affordability placed at the forefront of pricing decisions
- Consideration of potential patient out-of-pocket costs and barriers to treatment access



Practice Dynamics

- Designed with the operational realities of retina practices in mind
- Considers product access, reimbursement processes and the physician-administered treatment model



Extensive Stakeholder Research

- Grounded in comprehensive research across payers, providers and patients
- Evaluated from multiple perspectives to understand access expectations, adoption considerations and potential reimbursement barriers

Building the Commercial Infrastructure Designed Specifically For the Retina Market

Key Hiring Plans:

~30

Customer-facing commercial
personnel focused on
engaging retina practices

~20

Field reimbursement personnel
focused on supporting access
and reimbursement needs

Expanding medical affairs organization focused on scientific exchange, responding to medical inquiries, supporting appropriate use, and advancing evidence-generation initiatives

Europe **LYTENAVA™**

(bevacizumab gamma)

Commercial Launch Underway


Initial Launch Territories Include
Germany, United Kingdom, Austria

LYTENAVA™ European Commercial Launch Underway

First and Only Approved Ophthalmic Formulation of Bevacizumab for the Treatment of wet AMD

Now Commercially Available in Germany, the United Kingdom, and Austria

- ✓ Positive NICE recommendation
- ✓ Received 10 years market exclusivity covering 31 countries
- ✓ Real-world evidence study initiated in Germany



A Significant Opportunity for LYTENAVA™ in Europe

\$3.6 Billion Total European Anti-VEGF Retina Market¹

Off-Label Repackaged Bevacizumab
is Already Being Used in Europe as
First-Line Treatment for Wet AMD^{2,3,4}

2.8M

Injections
Annually

34%

of Total Anti-VEGF
Injections Annually

1.52 Million Number of
Treated Patients³

8.3 Million Total Anti-VEGF Units^{2,3,4}

1. Citeline (2023), Global Data (2023) and Market Scope (2022)
2. IQVIA MIDAS data Q3 2023
3. Graefe's Archive for Clinical and Experimental Ophthalmology (2020) 258:503–511 <https://doi.org/10.1007/s00417-019-04569-8>
4. Switzerland, Iceland and Norway are not EU member States

Expanding European Footprint for LYTENAVA™

Growing Presence Across Europe

Offices in London, Berlin, Amsterdam



Netherlands

Central hub for distribution
across the region



Germany

Now Available



Austria

Now Available



U.K.

Now Available



Netherlands

Target Launch
Early 2027
Initiating NE National
Reimbursement Submission



Switzerland

Target Launch 2027
Exclusive Commercial
Distribution Agreement
with Mediconsult AG

 **mediconsult**

Leadership Team with Ophthalmology and Launch Focus

Specialist Experience with Anti-VEGF Therapies



Bob Jahr
Chief Executive
Officer



**Kevin
Lundquist**
Chief Financial
Officer



**Jennifer
Kissner, PhD**
EVP Medical,
Clinical and
Regulatory Affairs



**Christopher
Yonan, PhD**
SVP, Technical
Operations



**Greg
DiPasquale**
SVP, Head of
Commercial
Operations



**Laura
Cantrell**
VP, Corporate
Strategy and
Business
Development



**Jennifer
Couture**
GCL/Global Head
of Legal,
Compliance, and
Internal Audit



Nearly
200 Years
of ophthalmology and launch
experience

Executive leadership within
51 companies

Launched
15 products
12 of which are in
ophthalmology

Corporate Summary

U.S.: Received FDA Approval with Commercial Launch Planned Before Calendar Year-end 2026


EU: Lytenava Commercially Available in Germany, the United Kingdom, and Austria

Targeting >\$15.9 Billion Global Anti-VEGF Retina Market Opportunity¹

Advancing Commercial
Infrastructure to Support
U.S. Launch

Approved in European Union
and United Kingdom
Covering 31 Countries

NASDAQ: OTLK
outlooktherapeutics.com



Investor Relations:
JTC Team, LLC.
otlk@jtcir.com
908-824-0775